These companies are making billions “managing” chronic diseases and life threatening disease. And I don’t believe only one pharmaceutical company is the devil here. They are all involved. Genzyme is suing Sanofi for buying the rights to market their drug for multiple sclerosis, scuttling it because they were supporting a competing drug. If a cure is invented, their collective actions will prevent us from getting it to market. In conjunction with corruption with members of the FDA, what drugs get to market are manipulated. Afrezza’s delayed release caused Mannkind to be in an extremely vulnerable position forcing Al Mann to make a deal whereby he would only get 35% percent of the profits and Sanofi 65%. He had to find someone to market and distribute his drug and the fact is all these companies who are in charge of our health are corrupt. They look at us as a business. There is a price on every head.
As an example:
Sanofi delayed drug to avoid $708 mln in payments, lawsuit claims
A new lawsuit accuses Sanofi SA of stalling development of its multiple sclerosis drug Lemtrada to avoid paying out at least $708 million to rights holders under its 2011 agreement to acquire Genzyme Corp.
The lawsuit, filed on Monday in Manhattan federal court by American Stock Transfer & Trust Co LLC, a trustee for the rights holders, seeks at least $236.1 million in damages.
Genzyme was in the process of developing Lemtrada when Sanofi bought it. Under the merger agreement, Sanofi issued Genzyme shareholders tradable certificates entitling them to payments if Lemtrada won approval from the U.S. Food and Drug Administration by March 31, 2014, and further payments if it met certain sales benchmarks after that.
Sanofi promised it would make “diligent efforts” to meet those goals, according to the complaint. Instead, the trustee alleges, it deliberately took a “slow path” to bring Lemtrada to market.
The lawsuit claims Sanofi deliberately ignored the FDA’s concerns about the designs of its clinical trials, leading the agency to deny the company’s first application for approval.
The trustee further claims that even after Lemtrada was finally approved in November 2014, Sanofi skimped on marketing it, while actively promoting a different multiple sclerosis drug, Aubagio. As a result, the lawsuit says, Lemtrada has failed to meet any of the sales benchmarks.
The drug is expected to lose patent protection in September 2017, according to the lawsuit, further limiting its prospects.
